Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.

Growing evidence highlights the peripheral blood mononuclear cells (PBMCs) role and the chemokine involvement in the Alzheimer's disease (AD) physiopathology. However, few data are available about the impact of AD PBMCs in the chemokine signature in a brain with AD phenotype. Therefore, this st...

Full description

Bibliographic Details
Main Authors: Julie Vérité, Guylène Page, Marc Paccalin, Adrien Julian, Thierry Janet
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6084889?pdf=render
id doaj-0d3980ddba444cbfb73a5fc77599e8e4
record_format Article
spelling doaj-0d3980ddba444cbfb73a5fc77599e8e42020-11-24T21:37:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01138e020123210.1371/journal.pone.0201232Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.Julie VéritéGuylène PageMarc PaccalinAdrien JulianThierry JanetGrowing evidence highlights the peripheral blood mononuclear cells (PBMCs) role and the chemokine involvement in the Alzheimer's disease (AD) physiopathology. However, few data are available about the impact of AD PBMCs in the chemokine signature in a brain with AD phenotype. Therefore, this study analyzed the chemokine levels in a human blood brain barrier model. A human endothelial cell line from the immortalized cerebral microvascular endothelial cell line (hCMEC/D3) and a human glioblastoma U-87 MG cell line, both with no AD phenotype were used while PBMCs came from AD at mild or moderate stage and control patients. PBMCs from moderate AD patients decreased CCL2 and CCL5 levels in endothelial, and also CXCL10 in abluminal compartments and in PBMCs compared to PBMCs from mild AD patients. The CX3CL1 expression increased in endothelial and abluminal compartments with PBMCs from mild AD patients compared to controls. AD PBMCs can convert the chemokine signature towards that found in AD brain, targeting some chemokines as new biomarkers in AD.http://europepmc.org/articles/PMC6084889?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Julie Vérité
Guylène Page
Marc Paccalin
Adrien Julian
Thierry Janet
spellingShingle Julie Vérité
Guylène Page
Marc Paccalin
Adrien Julian
Thierry Janet
Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
PLoS ONE
author_facet Julie Vérité
Guylène Page
Marc Paccalin
Adrien Julian
Thierry Janet
author_sort Julie Vérité
title Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
title_short Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
title_full Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
title_fullStr Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
title_full_unstemmed Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model.
title_sort differential chemokine expression under the control of peripheral blood mononuclear cells issued from alzheimer's patients in a human blood brain barrier model.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Growing evidence highlights the peripheral blood mononuclear cells (PBMCs) role and the chemokine involvement in the Alzheimer's disease (AD) physiopathology. However, few data are available about the impact of AD PBMCs in the chemokine signature in a brain with AD phenotype. Therefore, this study analyzed the chemokine levels in a human blood brain barrier model. A human endothelial cell line from the immortalized cerebral microvascular endothelial cell line (hCMEC/D3) and a human glioblastoma U-87 MG cell line, both with no AD phenotype were used while PBMCs came from AD at mild or moderate stage and control patients. PBMCs from moderate AD patients decreased CCL2 and CCL5 levels in endothelial, and also CXCL10 in abluminal compartments and in PBMCs compared to PBMCs from mild AD patients. The CX3CL1 expression increased in endothelial and abluminal compartments with PBMCs from mild AD patients compared to controls. AD PBMCs can convert the chemokine signature towards that found in AD brain, targeting some chemokines as new biomarkers in AD.
url http://europepmc.org/articles/PMC6084889?pdf=render
work_keys_str_mv AT julieverite differentialchemokineexpressionunderthecontrolofperipheralbloodmononuclearcellsissuedfromalzheimerspatientsinahumanbloodbrainbarriermodel
AT guylenepage differentialchemokineexpressionunderthecontrolofperipheralbloodmononuclearcellsissuedfromalzheimerspatientsinahumanbloodbrainbarriermodel
AT marcpaccalin differentialchemokineexpressionunderthecontrolofperipheralbloodmononuclearcellsissuedfromalzheimerspatientsinahumanbloodbrainbarriermodel
AT adrienjulian differentialchemokineexpressionunderthecontrolofperipheralbloodmononuclearcellsissuedfromalzheimerspatientsinahumanbloodbrainbarriermodel
AT thierryjanet differentialchemokineexpressionunderthecontrolofperipheralbloodmononuclearcellsissuedfromalzheimerspatientsinahumanbloodbrainbarriermodel
_version_ 1725938543035940864